

NAT13 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP5060b

Specification

NAT13 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession

<u>Q9GZZ1</u>

NAT13 Antibody (C-term) Blocking Peptide - Additional Information

Gene ID 80218

Other Names

N-alpha-acetyltransferase 50, 231-, N-acetyltransferase 13, N-acetyltransferase 5, hNAT5, N-acetyltransferase san homolog, hSAN, NatE catalytic subunit, NAA50, MAK3, NAT13, NAT5

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NAT13 Antibody (C-term) Blocking Peptide - Protein Information

Name NAA50 (HGNC:29533)

Function

N-alpha-acetyltransferase that acetylates the N-terminus of proteins that retain their initiating methionine (PubMed:<a href="http://www.uniprot.org/citations/19744929"

target="_blank">19744929, PubMed:22311970, PubMed:21900231, PubMed:27484799). Has a broad substrate specificity: able to acetylate the initiator methionine of most peptides, except for those with a proline in second position (PubMed:27484799). Also displays N-epsilon-acetyltransferase activity by mediating acetylation of the side chain of specific lysines on proteins (PubMed:<a href="http://www.uniprot.org/citations/19744929"

target="_blank">19744929). Autoacetylates in vivo (PubMed:19744929). The relevance of N-epsilon-acetyltransferase activity is however unclear: able to acetylate H4 in vitro, but this result has not been confirmed in vivo (PubMed:19744929). Component of N-alpha- acetyltransferase complexes containing NAA10 and NAA15, which has N-alpha-acetyltransferase activity (PubMed:<a href="http://www.uniprot.org/citations/16507339"



target=" blank">16507339, PubMed:29754825, PubMed:27484799, PubMed:32042062). Does not influence the acetyltransferase activity of NAA10 (PubMed:16507339, PubMed:27484799). However, it negatively regulates the N-alpha-acetyltransferase activity of the N-terminal acetyltransferase A complex (also called the NatA complex) (PubMed:32042062). The multiprotein complexes probably constitute the major contributor for N-terminal acetylation at the ribosome exit tunnel, with NAA10 acetylating all amino termini that are devoid of methionine and NAA50 acetylating other peptides (PubMed:16507339, PubMed:27484799). Required for sister chromatid cohesion during mitosis by promoting binding of CDCA5/sororin to cohesin: may act by counteracting the function of NAA10 (PubMed:17502424, PubMed:27422821).

Cellular Location

Cytoplasm. Nucleus Note=Localizes to the cytoplasm in interphase cells (PubMed:17502424)

NAT13 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

<u>Blocking Peptides</u>

NAT13 Antibody (C-term) Blocking Peptide - Images

NAT13 Antibody (C-term) Blocking Peptide - Background

NAT13 is probable catalytic component of the ARD1A-NARG1 complex which displays alpha (N-terminal) acetyltransferase activity.

NAT13 Antibody (C-term) Blocking Peptide - References

Starheim, K.K., et al. Mol. Cell. Biol. 29(13):3569-3581(2009)Polevoda, B., et al. BMC Proc 3 SUPPL 6, S2 (2009) Hou, F., et al. J. Cell Biol. 177(4):587-597(2007)